
ST. LOUIS (May 5, 2015)
ST. LOUIS, MO (May 5, 2015) – Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund III, L.P. at $80.2 million.
“This is a great time to be investing in drugs and therapeutic medical devices,” said RiverVest Managing Director Jay Schmelter. “There are many attractively valued investment opportunities in our space right now.”